<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704298</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-111</org_study_id>
    <nct_id>NCT03704298</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma</brief_title>
  <acronym>ZUMA-11</acronym>
  <official_title>A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Refractory Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are:

      Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and
      to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2

      Phase 2: To evaluate the efficacy of axicabtagene ciloleucel and utomilumab in participants
      with refractory large B-cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">February 2036</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Phase 1: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Dose-limiting toxicity is defined as protocol-defined axicabtagene ciloleucel related events with onset within the first 28 days following axicabtagene ciloleucel infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For Phase 2: Complete Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Complete response rate is defined as the incidence of a complete response per the Lugano Classification (Cheson et al, 2014), as determined by study investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Objective Response Rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Objective response rate is defined as the incidence of either a complete response (CR) or a partial response (PR) per Lugano Classification as determined by study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Duration of Response</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Among participants who experience an objective response, duration of response is defined as the date of their first objective response to disease progression per Lugano Classification as determined by study investigators or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Progression Free Survival</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Progression free survival is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano Classification as determined by study investigators or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Overall Survival</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Overall survival is defined as the time from axicabtagene ciloleucel infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Percentage of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to 24 months plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Percentage of Participants Experiencing Clinically Significant Changes in Safety Lab Values</measure>
    <time_frame>Up to 24 months plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Pharmacokinetics: Levels of Axicabtagene Ciloleucel in Blood</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 and Phase 2: Pharmacodynamics: Levels of Cytokines in Serum</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Refractory Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Axicabtagene ciloleucel plus utomilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel treatment on Day 0 plus utomilumab on study Day 1 or study Day 21 and continuing once every 4 weeks (Q4W) for 6 months or until Progressive Disease, whichever comes first.
Phase 2: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel and utomilumab based on the dose/regimen selected to move forward from the Phase 1 portion of the study as recommended by the internal Safety Review Team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene ciloleucel plus utomilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene ciloleucel plus utomilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>Axicabtagene ciloleucel plus utomilumab</arm_group_label>
    <other_name>Yescarta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Utomilumab</intervention_name>
    <description>Administered as an IV infusion</description>
    <arm_group_label>Axicabtagene ciloleucel plus utomilumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically proven large B-cell lymphoma including the following types:

               -  Diffuse large B cell lymphoma (DLBCL) not otherwise specified (ABC/GCB)

               -  High grade B-cell lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6
                  rearrangement

               -  DLBCL arising from follicular lymphoma

               -  T cell/histiocyte rich large B-cell lymphoma

               -  DLBCL associated with chronic inflammation

               -  Primary cutaneous DLBCL, leg type

               -  Epstein-Barr virus (EBV) + DLBCL

          -  Chemotherapy-refractory disease, defined as one or more of the following:

               -  No response to first-line therapy (primary refractory disease); subjects who are
                  intolerant to first-line therapy chemotherapy are excluded

                    -  Progressive disease (PD) as best response to first-line therapy

                    -  Stable disease (SD) as best response after at least 4 cycles of first-line
                       therapy (eg, 4 cycles of R-CHOP) with SD duration no longer than 6 months
                       from last dose of therapy

               -  No response to second or greater lines of therapy

                    -  PD as best response to most recent therapy regimen

                    -  SD as best response after at least 2 cycles of last line of therapy with SD
                       duration no longer than 6 months from last dose of therapy OR

               -  Refractory post-autologous stem cell transplant (ASCT)

                    -  Disease progression or relapsed . 12 months after ASCT (must have biopsy
                       proven recurrence in relapsed participant)

                    -  if salvage therapy is given post-ASCT, the participant must have had no
                       response to or relapsed after the last line of therapy

          -  At least 1 measureable lesion according to the Lugano Classification (Cheson et al,
             2014). Lesions that have been previously irradiated will be considered measurable only
             if progression has been documented following completion of radiation therapy.

          -  Participant must have received adequate prior therapy including at a minimum:

               -  Anti-CD20 monoclonal antibody unless investigator determines that tumor is
                  CD20-negative, and

               -  An anthracycline containing chemotherapy regimen

          -  No radiographic evidence, suspicion and/or history of central nervous system (CNS)
             involvement of lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Absolute neutrophil count (ANC) ≥ 1000/μL

          -  Platelet count ≥ 75,000/μL

          -  Absolute lymphocyte count ≥ 100/μL

          -  Adequate renal, hepatic, pulmonary, and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min

               -  Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 upper
                  limit of normal (ULN)

               -  Total bilirubin ≤ 1.5 mg/dL, except in individuals with Gilbert's syndrome.

               -  Cardiac ejection fraction ≥ 50% and no evidence of pericardial effusion within
                  180 days provided the subject did not receive an anthracycline-based treatment or
                  experience a cardiac event or change in performance status

               -  No clinically significant pleural effusion

               -  Baseline oxygen saturation &gt; 92% on room air

        Key Exclusion Criteria:

          -  Histologically proven primary mediastinal B-cell lymphoma (PMBCL)

          -  History of Richter's transformation of chronic lymphocytic lymphoma (CLL)

          -  Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy

          -  History of severe, immediate hypersensitivity reaction attributed to aminoglycosides

          -  History of HIV infection or acute or chronic active hepatitis B or C infection.
             Individuals with history of hepatitis infection must have cleared their infection as
             determined by standard serological and genetic testing per current Infectious Diseases
             Society of America (IDSA) guidelines or applicable country guidelines

          -  Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or
             a history of CNS lymphoma

          -  History or presence of CNS disorder, such as seizure disorder, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
             involvement

          -  Individuals with cardiac atrial or cardiac ventricular lymphoma involvement

          -  History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or
             other clinically significant cardiac disease within 12 months of enrollment

          -  Requirement for urgent therapy due to tumor mass effects (eg, blood vessel
             compression, bowel obstruction, or transmural gastric involvement

          -  Primary immunodeficiency

          -  History of autoimmune disease (eg, Crohn's, rheumatoid arthritis, systemic lupus)
             resulting in end organ injury or requiring systemic immunosuppression/systemic disease
             modifying agents within the last 2 years. Patients with a history of
             autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and
             patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be
             eligible for this study

          -  History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of
             enrollment

          -  Any medical condition likely to interfere with assessment of safety or efficacy of
             study treatment

          -  Autologous stem cell transplant within 6 weeks of planned enrollment

          -  Prior organ transplantation including prior allogeneic stem cell transplant (SCT)

          -  Use of any standard or experimental anti-cancer therapy within 2 weeks prior to
             enrollment, including cytoreductive therapy and radiotherapy, immunotherapy, or
             cytokine therapy (except for erythropoietin) Prior treatment with PD-L1 inhibitor,
             PD-1 inhibitor, anti-CTLA4, anti-CD137 (4-1BB), anti-OX40 or other immune checkpoint
             blockade or activator therapy

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
             pneumonitis per chest CT scan at screening. History of radiation pneumonitis in the
             radiation field (fibrosis) is allowed

          -  In the investigator's judgment, the subject is unlikely to complete all
             protocol-required study visits or procedures, including follow-up visits, or comply
             with the study requirements for participation.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>1-844-454-5483(1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Sharan</last_name>
      <phone>650-721-4091</phone>
      <email>sharanc@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>David Miklos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/ Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Crosetti</last_name>
      <phone>310-825-7412</phone>
      <email>acrosetti@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Timmerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Boyd</last_name>
      <phone>813-745-4201</phone>
      <email>Joseph.Boyd@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jain Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rocchio</last_name>
      <phone>617-632-5221</phone>
      <email>MichaelJ_Rocchio@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Caron Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gould</last_name>
      <phone>212-305-6361</phone>
    </contact>
    <investigator>
      <last_name>Ran Reshef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

